Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials Szuba A; Podgorski MPharmacol Rep 2006[]; 58 Suppl (ä): 16-20There is a growing clinical evidence to support the hypothesis that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase is a new independent cardiovascular risk factor. ADMA mediates endothelial dysfunction in lipid disorders, coronary artery disease, chronic heart failure, diabetes mellitus and hypertension. The aim of this review was to summarize the latest evidence from epidemiological and prospective clinical trials and to emphasize the role of ADMAas a cardiovascular risk factor.|Arginine/*analogs & derivatives/blood/metabolism/pharmacology[MESH]|Biomarkers/blood[MESH]|Cardiovascular Diseases/blood/*metabolism[MESH]|Clinical Trials as Topic[MESH]|Cross-Sectional Studies[MESH]|Endothelium, Vascular/enzymology[MESH]|Humans[MESH]|Nitric Oxide Synthase/antagonists & inhibitors[MESH]|Nitric Oxide/metabolism[MESH]|Prospective Studies[MESH]|Risk Factors[MESH] |